Navigation Links
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Date:5/14/2008

ncer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding Poniard's (the "Company's") business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and the Company's Quarterly Report for the period ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any f
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today reported ... 2011. "We are focused on submitting our ... letter around year-end and filing the lorcaserin marketing authorization ... half of next year," stated Jack Lief, Arena,s President ...
... Nov. 9, 2011 Jay Yadav, M.D. , ... of the Year Award by the Association of Telecom ... medical device company that has developed and is commercializing ... human body. Dr. Yadav won the award in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 2The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 3
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... healthcare communities throughout ... ... of,Health IT Conference and Exhibition in Copenhagen, Microsoft Corp. and the,Healthcare ... Health Users Group (Microsoft HUG) across,Europe, the Middle East and Africa ...
... 4 Kaiser Foundation Health Plan,Inc., Kaiser Foundation ... of $10.2 billion for the quarter ended September,30, ... period last year., KFHP/H,s operating income in ... million in the same quarter last year. Financial ...
... Calif., Nov. 4 XTENT, Inc.,(Nasdaq: XTNT ) today ... September 30, 2008., The company reported a net loss ... of 2008, compared to a net loss of $9.5 million, ... the nine months ended,September 30, 2008, XTENT had a net ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (the ... had received a NASDAQ Staff Deficiency Letter indicating ... 4310(c)(7). This rule,requires the Company to maintain a ... on the NASDAQ Capital Market. For purposes of ...
... VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated ... 2008 to,discuss its 2008 third quarter financial results., ... To participate in the conference call, please dial ... at least 15 minutes,before the start of the call. ...
... N.Y. -- Researchers at the University at Buffalo have ... in utero to develop obesity in adulthood. , Moreover, ... metabolic programming occurs in the fetal hypothalamus, the area ... homeostasis (body weight) throughout life. , Levels of the ...
Cached Medicine News:Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 2Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 4Health News:XTENT Announces Third Quarter 2008 Financial Results 2Health News:XTENT Announces Third Quarter 2008 Financial Results 3Health News:XTENT Announces Third Quarter 2008 Financial Results 4Health News:WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7) 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Maternal obesity can program fetal brain to induce adult-onset obesity 2
Inquire...
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Single-action scissors offer fine-pointed, sharp dissecting jaws to facilitate a partial cut in the cystic duct in preparation for a cholangiogram. They are tapered at the tip for greater visualizati...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: